BioCatalystWatch
QUREWorkspace / QURE / OverviewCompany library
Price
Market cap
Next catalystMay 1, 2027Ifezuntirgene inilparvovec (AMT-130) — U.S. and European Phase I/II studies · Regulatory decisionCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

AMT-260

GRIK2 (GluK2)

PreINDP1P2P3FilingApproved
Upcoming / outlook

AMT-191

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

AMT-260

GRIK2 (GluK2)

PreINDP1P2P3FilingApproved
Upcoming / outlook

AMT-191

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

AMT-230

Alpha-synuclein

PreINDP1P2P3FilingApproved
AMT-160

PreINDP1P2P3FilingApproved

Approved / commercial

Approved

PreINDP1P2P3FilingApproved

History / paused

PreINDP1P2P3FilingApproved

C9ORF72

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

QURE PR & News

PR & News

QURE SEC archive